In general, it feels like the Trump government has been bad for ltr pharma over the last 6 months, and I think that would be the same for a lot of stocks. For me, there's some concern around the speed of future approvals, and the potential attitude of new fda management towards these types of drugs, even though they might be wrong about that. Hopefully some of this is priced into the current share price already.
Add to My Watchlist
What is My Watchlist?
